HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Split Decision In Breach-of-Contract Battle Of Litigation War Between ChromaDex, Elysium

Consolidated Advertising Complaints Continue, ChromaDex Appeals Patent-Infringement Loss

Executive Summary

California federal court jury found both breached contracts: Elysium failed to pay for nicotinamide riboside and pterostilbene it ordered and received, while ChromaDex violated pricing provision in supply agreement.

You may also be interested in...



Attention Shoppers And Investors: ChromaDex Makes Tru Niagen Available At Walmart

Tru Niagen products available at 3,800 US Walmart stores include a lower dose, 100 mg, that ChromaDex didn't previously market. Launch sparks heavy trading driving up firm's share price.

ChromaDex Supplies ‘Healthy Aging’ Ingredient To Male Supplement Brand

ChromaDex Corp. agrees to supply its ‘healthy aging’ nicotinamide riboside ingredient Niagen to New York-based healthcare technology firm Roman Health Ventures, Inc., which plans to use it in its men’s supplement line. ChromaDex’ total sales in the first quarter rose 2% to $14.7m.

ChromaDex Hits Consumer Brand Marketing Sweet Spot With Former Nestle Executive In Charge

Tru Niagen supplement firm names Fadi Karam CMO a little more than a month after it announced a distribution deal to put its nicotinamide riboside supplement on shelves at US Walmart stores.

Related Content

Topics

UsernamePublicRestriction

Register

RS151815

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel